Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221857 · ClinicalTrials.gov registry record · Phase 1
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
A Phase 1 study, sponsored by Gamida Cell.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01221857 is a Phase 1 study that has completed, run by Gamida Cell. The registered enrollment target is 12 participants.
The verdict
NCT01221857, a Phase 1 study, has completed, sponsored by Gamida Cell.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
Interventions
- DRUG NiCord®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221857
The ClinicalTrials.gov registry entry for NCT01221857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NiCord® is the first listed.
NCT01221857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01221857 about?
NCT01221857 is a clinical study titled "Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies". Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
What is the current status of trial NCT01221857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01221857?
The interventions under investigation include: NiCord® (DRUG).
Who is sponsoring clinical trial NCT01221857?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.